COMMUNIQUÉS West-GlobeNewswire

MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
11/08/2026
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
Solésence Reschedules Second Quarter 2026 Conference Call to August 19
11/08/2026
ROMEOVILLE, Ill., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company has [...]
Dallas Hair Replacement for Business Professionals Offers Non-Surgical Hair Replacement for Men
10/08/2026
Look Sharp, Stay Competitive. Restore your confidence with non-surgical hair replacement in Dallas. Dallas, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) -- In the competitive business environment of Dallas, confidence and success [...]
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
10/08/2026
Q2 Revenue of $9.1 million Q2 Income from Continuing Operations of $0.3 million Q2 Thyroid volume year-over-year increase of 6% Q2 Thyroid revenue year-over-year increase of 9% Trailing twelve-month thyroid revenue of $ [...]
Essential Amino Acid Intake Draws Focus During GLP-1 Therapy as Oh!mino Targets Muscle Loss
10/08/2026
Seal Beach, CA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Oh!Nutrition, a California-based nutritional product development company, today announced Oh!mino® Muscle Synthesis Activator, an essential amino acid supplement [...]
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2 [...]
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
10/08/2026
Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a [...]
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
10/08/2026
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 [...]
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
10/08/2026
The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation [...]
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
10/08/2026
Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of [...]
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
10/08/2026
Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical [...]
Ceribell Reports Second Quarter 2026 Financial Results
10/08/2026
SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
10/08/2026
TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. Alignment with FDA on earlier ORIGIN 3 final [...]
Harrow Announces Second Quarter 2026 Financial Results
10/08/2026
Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year Reiterated full-year 2026 financial guidance of $350 million to $365 million in [...]
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
10/08/2026
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) – – Presented DMR-001 preclinical data at the [...]
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
10/08/2026
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion [...]
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
10/08/2026
Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company [...]
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
10/08/2026
One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence [...]
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
10/08/2026
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for- [...]

Pages